ING Groep NV Sells 250,555 Shares of Insmed, Inc. $INSM

ING Groep NV lessened its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 67.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 122,945 shares of the biopharmaceutical company’s stock after selling 250,555 shares during the quarter. ING Groep NV’s holdings in Insmed were worth $21,397,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Havemeyer Place LP bought a new stake in shares of Insmed during the 4th quarter valued at about $1,025,000. Vestcor Inc bought a new stake in shares of Insmed during the 4th quarter valued at about $738,000. Fjarde AP Fonden Fourth Swedish National Pension Fund bought a new stake in shares of Insmed during the 4th quarter valued at about $8,789,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Insmed during the 4th quarter valued at about $261,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in shares of Insmed during the 4th quarter valued at about $2,011,000.

Insmed Price Performance

Shares of Insmed stock opened at $94.22 on Monday. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The business’s 50 day simple moving average is $130.45 and its two-hundred day simple moving average is $154.65. The stock has a market capitalization of $20.42 billion, a P/E ratio of -16.39 and a beta of 0.79. Insmed, Inc. has a one year low of $70.57 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.42) EPS. Analysts forecast that Insmed, Inc. will post -2.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on INSM shares. HC Wainwright reissued a “buy” rating on shares of Insmed in a report on Friday, May 8th. Bank of America raised their price objective on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Wells Fargo & Company decreased their price objective on Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Mizuho raised their price objective on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Finally, Roth Mkm reissued a “buy” rating and set a $212.00 price objective on shares of Insmed in a report on Friday, April 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.50.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $43,361,604.45. The trade was a 3.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the transaction, the insider directly owned 51,871 shares in the company, valued at $7,831,483.58. This trade represents a 27.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 160,482 shares of company stock valued at $24,438,193 over the last quarter. Company insiders own 2.10% of the company’s stock.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.